J Neuroimmunol. 2004 Jun;151(1-2):66-77
Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd.
Alzheimer's Research Center, Regions Hospital, 640 Jackson St., St.
Paul, MN 55101, USA.
Intranasal (IN) administration of IFNbeta-1b was examined as a route for targeted delivery to the rat central nervous system (CNS).
Intranasal administration resulted in significant delivery throughout the CNS and cervical lymph nodes with low delivery to peripheral organs.
At similar blood levels, intravenous (IV) administration of IFNbeta-1b yielded 88-98% lower CNS levels and 100-1650% greater peripheral organ levels compared to intranasal.
Autoradiography confirmed much greater delivery to the CNS with intranasal administration.
Intranasally administered IFNbeta-1b reached the brain intact and produced tyrosine phosphorylation of IFN receptor in the CNS.
Intranasal administration offers a non-invasive method of drug delivery for multiple sclerosis (MS) that bypasses the blood-brain barrier (BBB) and directly targets the CNS and lymph nodes.